BeiGene, Ltd. — 2018 Form 10-K Summary
Business context and reporting period
BeiGene is a commercial-stage biotechnology company focused on oncology drug development and commercialization. This 10-K covers the fiscal year ended December 31, 2018; the filing also reports unaudited fourth-quarter results. Its marketed products in China were licensed from Celgene (ABRAXANE, REVLIMID and VIDAZA). Its leading internally developed candidates—zanubrutinib, tislelizumab and pamiparib—remained investigational at year-end.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Total revenue | $198.2 million | $238.4 million |
| Product revenue, net | $130.9 million | $24.4 million |
| Collaboration revenue | $67.3 million | $214.0 million |
| Research and development expense | $679.0 million | $269.0 million |
| Selling, general and administrative expense | $195.4 million | $62.6 million |
| Operating loss | $705.8 million | $98.5 million |
| Net loss attributable to BeiGene | $673.8 million | $93.1 million |
| Operating cash flow | $(547.7) million | $12.8 million |
For Q4 2018, revenue was $58.7 million, operating loss was $280.8 million, and net loss was $266.7 million, compared with Q4 2017 revenue of $18.2 million and net loss of $99.3 million. Q4 diluted loss per share was $0.35.
Product cost of sales was $28.7 million against $130.9 million of net product revenue, implying an approximate product gross margin of 78%; this is not a consolidated margin measure. At December 31, 2018, cash, cash equivalents and restricted cash totaled $740.7 million, with short-term investments of $1.069 billion. Working capital was $1.697 billion; total assets were $2.250 billion and total liabilities were $496.0 million. Interest-bearing debt was approximately $198.4 million, including a $148.9 million shareholder loan and bank loans. No dividends were paid or expected in the foreseeable future.
Material changes versus prior period
- Revenue fell 17% year over year despite a more than fivefold increase in product revenue, because 2017 included substantial upfront Celgene license revenue; 2018 collaboration revenue was mainly R&D reimbursement and services.
- R&D expense rose 152% and SG&A rose 212%, reflecting expanded clinical programs, personnel, commercial operations and infrastructure.
- Net loss widened to $674.0 million from $93.3 million; operating cash flow shifted from a $12.8 million inflow to a $547.7 million outflow.
- Two 2018 equity offerings generated approximately $1.6 billion in net proceeds. Cash, cash equivalents and restricted cash increased by $501.1 million during the year.
Outlook, commentary and key risks
- Management said existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements. It also stated that additional funding would be required to complete all planned global development and commercial launches.
- Management expected 2019 product revenue to benefit from promotion and reimbursement work for ABRAXANE and REVLIMID and VIDAZA commercialization. It planned additional submissions and potential launches in China and the United States in 2019–2020, subject to clinical and regulatory outcomes. No quantified earnings or revenue guidance was provided.
- In January 2019, FDA granted zanubrutinib Breakthrough Therapy designation for certain MCL patients. China applications for zanubrutinib in R/R MCL and CLL/SLL and tislelizumab in R/R cHL had priority review; approval was not assured.
- R&D included $89 million of upfront or termination-related collaboration costs, including payments relating to Mirati, Zymeworks and termination of the Merck KGaA pamiparib arrangement. The company also reported $70 million of acquired in-process R&D cash outlays related to licensing arrangements.
- BeiGene expected the proposed Bristol Myers Squibb acquisition of Celgene could trigger termination of Celgene’s tislelizumab license outside Asia; the filing anticipated regaining rights and receiving a termination fee, but the transaction and outcome remained contingent.
- Principal risks include clinical-trial and approval uncertainty, rising cash burn and potential dilution from future financing, commercial competition and reimbursement, manufacturing scale-up and third-party supply, intellectual-property disputes, evolving China regulation and currency controls. The filing also notes the auditor’s China-based work was not fully inspectable by the PCAOB.
Investor verification priorities
- Check the full audited statements and notes for debt maturities, interest terms, cash restrictions and the availability of funds held by the Guangzhou joint venture.
- Track clinical results, regulatory decisions and confirmatory-study requirements for zanubrutinib, tislelizumab and pamiparib; priority review and designations do not ensure approval.
- Verify the status and financial terms of the Celgene/BMS transaction, any tislelizumab license termination and associated funding or termination payments.
- Assess whether product revenue growth, reimbursement access and commercial margins can keep pace with operating cash use and planned R&D and manufacturing investment.
- Review the underlying quarterly disclosures and licensing notes for the timing and classification of collaboration revenue, upfront R&D charges and other unusual items.